YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.

J Transl Med 2013 Sep 18;11:216. Epub 2013 Sep 18.

Institut für Experimentelle Onkologie & Therapieforschung, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, 81675 München, Germany.

Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence. In brain CSC, the PI3-K/AKT and the RAS/mitogen activated protein kinase (MAPK) pathways are found to be activated. In consequence, the human transcription factor YB-1, knowing to be responsible for the emergence of drug resistance and driving adenoviral replication, is phosphorylated and activated. With this knowledge, YB-1 was established in the past as a biomarker for disease progression and prognosis. This study determines the expression of YB-1 in glioblastoma (GBM) specimen in vivo and in brain CSC lines. In addition, the capacity of Ad-Delo3-RGD, an YB-1 dependent oncolytic adenovirus, to eradicate CSC was evaluated both in vitro and in vivo.

Methods: YB-1 expression was investigated by immunoblot and immuno-histochemistry. In vitro, viral replication as well as the capacity of Ad-Delo3-RGD to replicate in and, in consequence, to kill CSC was determined by real-time PCR and clonogenic dilution assays. In vivo, Ad-Delo3-RGD-mediated tumor growth inhibition was evaluated in an orthotopic mouse GBM model. Safety and specificity of Ad-Delo3-RGD were investigated in immortalized human astrocytes and by siRNA-mediated downregulation of YB-1.

Results: YB-1 is highly expressed in brain CSC lines and in GBM specimen. Efficient viral replication in and virus-mediated lysis of CSC was observed in vitro. Experiments addressing safety aspects of Ad-Delo3-RGD showed that (i) virus production in human astrocytes was significantly reduced compared to wild type adenovirus (Ad-WT) and (ii) knockdown of YB-1 significantly reduced virus replication. Mice harboring othotopic GBM developed from a temozolomide (TMZ)-resistant GBM derived CSC line which was intratumorally injected with Ad-Delo3-RGD survived significantly longer than mice receiving PBS-injections or TMZ treatment.

Conclusion: The results of this study supported YB-1 based virotherapy as an attractive therapeutic strategy for GBM treatment which will be exploited further in multimodal treatment concepts.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-11-216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848904PMC
September 2013

Publication Analysis

Top Keywords

brain csc
12
yb-1
9
cancer stem
8
csc
8
csc lines
8
capacity ad-delo3-rgd
8
human astrocytes
8
viral replication
8
tumor growth
8
gbm specimen
8
yb-1 dependent
8
dependent oncolytic
8
oncolytic adenovirus
8
gbm
6
ad-delo3-rgd
5
consequence kill
4
intratumorally injected
4
kill csc
4
csc determined
4
csc intratumorally
4

Similar Publications